Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487093 | 0.92 | MAP2K1 (0.39) | MAP2K1MEN1TP53HPGDKMT2A | |
| SCHEMBL4142320 | 0.87 | BRPF1 (0.35) | MAP2K1MEN1TP53HPGDKMT2A | |
| SCHEMBL4146815 | 0.81 | LMNA (0.34) | MEN1TP53HPGDKMT2A | |
| SCHEMBL12656472 | 0.78 | MAP2K1 (0.33) | MAP2K1TSHRHSD17B10CASP3 | |
| SCHEMBL487042 | 0.78 | MAP2K1 (0.32) | MAP2K1 | |
| SCHEMBL12126919 | 0.74 | MAP2K1 (0.33) | MAP2K1 | |
| SCHEMBL392974 | 0.73 | — | — | |
| SCHEMBL1341242 | 0.72 | — | — | |
| SCHEMBL487017 | 0.71 | MAP2K1 (0.36) | MAP2K1 | |
| SCHEMBL387037 | 0.71 | MAP2K1 (0.34) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411366-B1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2411366-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | Ardea Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108652-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | BRAF, NRAS, MAP3K12 | MAP2K1 59/4885TSHR 3675/4885HSD17B10 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.